Navigation Links
Spectral diagnostics Raises $14 million and enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis
Date:12/17/2009

added to conventional therapy, significantly improved hemodynamics and organ dysfunction, and reduced 28-day mortality in patients with severe sepsis and septic shock in comparison to those patients in the conventional therapy group.

Terms of the Financing

Under the terms of the financing (the "Financing") the Company will issue 35,000,000 units of the Company (the "Units") at a price of $0.40 per Unit to BioMS and GrowthWorks WV Management Ltd. and certain of its affiliates (collectively, "GrowthWorks"), for aggregate gross proceeds of $14 million. Each Unit consists of one common share of the Company ("Common Share") and one half of one Common Share purchase warrant (each whole Common Share purchase warrant, a "Warrant") entitling the holder thereof to acquire one Common Share at a price of $0.60 per Common Share for a period of four years from Closing.

BioMS will invest $12 million to acquire 30,000,000 Units under the Financing, and following Closing will hold 30,000,000 Common Shares, representing approximately 48% of the issued and outstanding Common Shares, calculated on a non-diluted basis, after giving effect to the Proposed Transactions (as defined below). BioMS will also be issued 15,000,000 Warrants in the Financing. GrowthWorks will invest $2 million in the Financing.

In connection with the Financing, and as partial consideration for services performed, at Closing, the Company will also issue broker warrants to Desjardins Securities Inc., who acted as agent for the Financing, which will entitle them to acquire 1,050,000 Common Shares at an exercise price of $0.40 per Common Share, and a further 525,000 Common Shares at an exercise price of $0.60 per Common Share, in each case, for a period of four years from Closing.

At Closing, the Company has also agreed to issue 2,890,625 Common Shares to GrowthWorks at a deemed price of $0.40 per Common Share as full repayment and final settlement of a non-in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. First Spaceborne Hyperspectral Imager Will Use QImaging Rolera-MGi EMCCD Camera
2. Spectral appoints new board member
3. Spectral announces second quarter 2009 results
4. Spectral announces publication demonstrating Toraymyxin(TM) significantly reduces mortality from sepsis in prospective controlled trial
5. Spectral announces first quarter 2009 results
6. Spectral announces presentations at the 29TH International Symposium on Intensive Care and Emergency Medicine focusing on the role of endotoxin
7. Spectral announces 2008 financial results
8. Spectral signs exclusive license agreement to bring sepsis therapeutic to the U.S. market
9. Surface plasmon resonances of metal nanoparticles in array can have narrower spectral widths
10. Spectral announces third quarter 2008 results
11. Spectral to bring anti-sepsis therapy to the U.S. market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... 26, 2015 , ... MediVet Biologics, a leader in Veterinary ... to open in Manhattan, Kansas in early October, 2015. The location of the ... and development through collaboration with researchers from Kansas State University’s College of Veterinary ...
(Date:8/26/2015)... , ... August 26, 2015 , ... ... increasing its investment in the development and manufacture of highly valued cardiac markers ... company’s scientific team's extensive expertise with protein chemistry has led to the development ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation ... announced today the closing of its previously announced public ... by the underwriters of their option to purchase an ... offering price of $41.00 per share.  The exercise of ... of common stock sold by Intrexon to 5,609,756 shares ...
(Date:8/26/2015)... OXFORD, England , August 26, 2015 ... P2i Ltd against Europlasma NV relating to P2i ... parties have resolved their dispute in the United ... or liability on the part of either party. As a ... the Central District of California dismissed ...
Breaking Biology Technology:MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4P2i Settles United States Litigation 2
... Next Generation Cellulosic Feedstock Program, KINGSTON, ... Inc. (PPI) has,announced today that it has ... non-food crops for industries seeking renewable,feedstocks for ... The facility, located in Waterloo, New York, ...
... -, BRIDGEWATER, N.J. and NEW YORK, June 18 ... launch backed by Warburg Pincus, the leading global private ... GANIC from Warburg,Pincus Private Equity X, L.P., a $15 ... was founded by a highly seasoned group of senior,executives ...
... Alexion,Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that ... present at the,Jefferies & Co. 2nd Annual Healthcare Conference ... June 25, 2008., An audio webcast of Dr. ... webcast at: http://www.alexionpharm.com . An archived version of ...
Cached Biology Technology:Performance Plants Establishes U.S. Biofuels Facility 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 3
(Date:8/10/2015)... Germany , August 10, 2015 /PRNewswire/ ... world leader in Eye Tracking Technology for more than ... Eye Tracking Platform for integration into all consumer display ... designs for seamless integration of eye tracking into consumer ... and augmented reality smart glasses. Omnivision,s leading sensor technology ...
(Date:8/5/2015)... , August 5, 2015 ... & Access Management Market by Software, Services, Vertical (BFSI, Airport, ... & Geography - Global Forecast to 2020", published by ... Management Market globally into various segments. The global PIAM ... 2014 to $546.2 Million by 2019, at a CAGR ...
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... Scientists at the Weizmann Institute of Science recently discovered ... bones. Their findings were published in the Proceedings of ... is a potential source of information on the evolution, ... humans. But if it is not well preserved or ...
... for decades to determine the chemical composition of ... identify viruses, and never in complex environmental samples. ... School of Public Health recently demonstrated that proteomic ... for this purpose. Using a two-step process, researchers ...
... who have induced heart cells in culture to mimic ... to gain new insight into the mechanisms that spawn ... revealed that while electric shocks such as those delivered ... they cause them to accelerate and multiply. , The ...
Cached Biology News:Ancient fossil DNA found preserved in crystal 2Ancient ants arose 140-168 million years ago 2Engineered heart tissue offers insights into irregular heartbeats, defibrillator failure 2Engineered heart tissue offers insights into irregular heartbeats, defibrillator failure 3
SMVT (N-14)...
...
... is a cytidine analog that has been shown ... Immunogen: Chemical / Small Molecule conjugated ... of the ddC antiserum was determined by calculating ... moles of ddC analog at the 50% intercept ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
Biology Products: